|
8 Companies |
|
4 Products |
|
4 Products |
|
17 Mechanisms of Action |
|
0 Trials |
|
63 News |
|
| 12» |
- ||| Trial completion, Trial completion date, Trial primary completion date: Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood (clinicaltrials.gov) - Feb 22, 2018
P=N/A, N=3819, Completed, Sponsor: CHU de Quebec-Universite Laval
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Jun 2017 | Trial completion date: Dec 2017 --> Jun 2017
- || Trial primary completion date: Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood (clinicaltrials.gov) - Jan 31, 2017
P=N/A, N=3819, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Qu
Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Jun 2017 | Trial completion date: Dec 2017 --> Jun 2017 Trial primary completion date: Oct 2016 --> Sep 2017
- Trial completion, Enrollment change: X-chromosome Inactivation, Epigenetics and the Transcriptome (clinicaltrials.gov) - May 24, 2016
P=N/A, N=110, Completed, Sponsor: University of Aarhus
Trial primary completion date: Oct 2016 --> Sep 2017 Active, not recruiting --> Completed | N=395 --> 110
- || Enrollment closed, Enrollment change: Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood (clinicaltrials.gov) - May 3, 2016
P=N/A, N=3819, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Qu
Active, not recruiting --> Completed | N=395 --> 110 Recruiting --> Active, not recruiting | N=5600 --> 3819
- ||| Trial completion: Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=3333, Completed, Sponsor: Sequenom, Inc.
Recruiting --> Active, not recruiting | N=5600 --> 3819 Active, not recruiting --> Completed
- ||| Trial completion: Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=3062, Completed, Sponsor: Sequenom, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial completion, Trial primary completion date: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 7, 2016
P2, N=82, Completed, Sponsor: Onconova Therapeutics, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2015
- ||| Trial completion: Prenatal Screening for Down Syndrome With DNAFirst (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=100, Completed, Sponsor: Women and Infants Hospital of Rhode Island
Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2015 Active, not recruiting --> Completed
- Enrollment change, Trial termination, Trial primary completion date: Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21 (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=370, Terminated, Sponsor: OVO R & D
Active, not recruiting --> Completed N=2000 --> 370 | Recruiting --> Terminated | Trial primary completion date: Apr 2017 --> Jun 2015; The technique has been approved and validated
- || Enrollment closed, Trial primary completion date: Prenatal Screening for Down Syndrome With DNAFirst (clinicaltrials.gov) - Jul 17, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: Women and Infants Hospital of Rhode Island
N=2000 --> 370 | Recruiting --> Terminated | Trial primary completion date: Apr 2017 --> Jun 2015; The technique has been approved and validated Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jul 2015
- || Enrollment closed, Trial primary completion date: X-chromosome Inactivation, Epigenetics and the Transcriptome (clinicaltrials.gov) - Jun 29, 2015
P=N/A, N=395, Active, not recruiting, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Jul 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Oct 2015
- ||| Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Enrollment closed: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - May 4, 2015
P2, N=80, Active, not recruiting, Sponsor: Onconova Therapeutics, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Oct 2015 Recruiting --> Active, not recruiting
- || Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial primary completion date: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 19, 2015
P2, N=80, Recruiting, Sponsor: Onconova Therapeutics, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Sep 2015
- || Trial primary completion date: Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies (clinicaltrials.gov) - Dec 12, 2014
P=N/A, N=3333, Active, not recruiting, Sponsor: Sequenom, Inc.
Trial primary completion date: Mar 2015 --> Sep 2015 Trial primary completion date: Jun 2014 --> Feb 2014
- || Enrollment closed, Enrollment change: Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies (clinicaltrials.gov) - Dec 12, 2014
P=N/A, N=3062, Active, not recruiting, Sponsor: Sequenom, Inc.
Trial primary completion date: Jun 2014 --> Feb 2014 Recruiting --> Active, not recruiting | N=2200 --> 3062
- || Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial primary completion date: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - Nov 10, 2014
P2, N=80, Recruiting, Sponsor: Onconova Therapeutics, Inc.
Recruiting --> Active, not recruiting | N=2200 --> 3062 Trial primary completion date: Oct 2014 --> Mar 2015
- ||| Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Enrollment change: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 15, 2014
P2, N=80, Recruiting, Sponsor: Onconova Therapeutics, Inc.
Trial primary completion date: Oct 2014 --> Mar 2015 N=60 --> 80
- ||| Trial completion: Non-invasive Chromosomal Examination of Trisomy Study (clinicaltrials.gov) - Jul 14, 2014
P=N/A, N=18955, Completed, Sponsor: Ariosa Diagnostics, Inc
N=60 --> 80 Active, not recruiting --> Completed
- ||| Enrollment open: Prenatal Screening for Down Syndrome With DNAFirst (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=100, Recruiting, Sponsor: Women and Infants Hospital of Rhode Island
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Enrollment open, Trial initiation date: Prenatal Screening for Down Syndrome With DNAFirst (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=100, Not yet recruiting, Sponsor: Women and Infants Hospital of Rhode Island
Not yet recruiting --> Recruiting Initiation date: Nov 2013 --> Mar 2014 | Not yet recruiting --> Recruiting
- || Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial primary completion date: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - May 25, 2014
P2, N=60, Recruiting, Sponsor: Onconova Therapeutics, Inc.
Initiation date: Nov 2013 --> Mar 2014 | Not yet recruiting --> Recruiting Trial primary completion date: Apr 2014 --> Oct 2014
- || Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial completion date: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - May 25, 2014
P2, N=60, Recruiting, Sponsor: Onconova Therapeutics, Inc.
Trial primary completion date: Apr 2014 --> Oct 2014 Trial completion date: Oct 2014 --> Mar 2015
- Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial primary completion date: Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk (clinicaltrials.gov) - Apr 9, 2014
P2, N=14, Completed, Sponsor: Onconova Therapeutics, Inc.
Trial completion date: Oct 2014 --> Mar 2015 Trial primary completion date: Aug 2012 --> Nov 2013
- Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial completion date: Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk (clinicaltrials.gov) - Apr 9, 2014
P2, N=14, Completed, Sponsor: Onconova Therapeutics, Inc.
Trial primary completion date: Aug 2012 --> Nov 2013 Trial completion date: Aug 2012 --> Nov 2013
- || Enrollment closed: Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies (clinicaltrials.gov) - Jan 15, 2014
P=N/A, N=3000, Active, not recruiting, Sponsor: Sequenom, Inc.
Trial completion date: Aug 2012 --> Nov 2013 Recruiting --> Active, not recruiting
- erlotinib / Generic mfg.
Enrollment change: Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) (clinicaltrials.gov) - Jan 8, 2014
P1, N=6, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting N=16 --> 6
- erlotinib / Generic mfg.
Trial completion: Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) (clinicaltrials.gov) - Jan 8, 2014
P1, N=6, Completed, Sponsor: Mayo Clinic
N=16 --> 6 Recruiting --> Completed
- Enrollment change: SEQ21: Trisomy of Chromosome 21 Diagnosis by High Output Sequencing (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=976, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed N=255 --> 976
- Trial completion: SEQ21: Trisomy of Chromosome 21 Diagnosis by High Output Sequencing (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=976, Completed, Sponsor: Assistance Publique - H
N=255 --> 976 Recruiting --> Completed
- Trial initiation date: Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=5600, Recruiting, Sponsor: Centre Hospitalier Universitaire de Qu
Recruiting --> Completed Initiation date: Aug 2013 --> Nov 2013
- Enrollment open: Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=5600, Recruiting, Sponsor: Centre Hospitalier Universitaire de Qu
Initiation date: Aug 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- || Enrollment change: Non-invasive Chromosomal Examination of Trisomy Study (clinicaltrials.gov) - Aug 14, 2013
P=N/A, N=18955, Active, not recruiting, Sponsor: Ariosa Diagnostics, Inc
Not yet recruiting --> Recruiting N=25000 --> 18955
- || Enrollment closed: Non-invasive Chromosomal Examination of Trisomy Study (clinicaltrials.gov) - Aug 14, 2013
P=N/A, N=18955, Active, not recruiting, Sponsor: Ariosa Diagnostics, Inc
N=25000 --> 18955 Recruiting --> Active, not recruiting
- || Enrollment change: Non-invasive Prenatal Diagnostic Validation Study (clinicaltrials.gov) - Jun 27, 2013
P=N/A, N=1781, Completed, Sponsor: Natera, Inc.
Recruiting --> Active, not recruiting N=4640 --> 1781
- ||| Trial completion: Non-invasive Prenatal Diagnostic Validation Study (clinicaltrials.gov) - Jun 27, 2013
P=N/A, N=1781, Completed, Sponsor: Natera, Inc.
N=4640 --> 1781 Recruiting --> Completed
- Enrollment open: X-chromosome Inactivation, Epigenetics and the Transcriptome (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=395, Recruiting, Sponsor: University of Aarhus
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Trial completion: Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk (clinicaltrials.gov) - Jan 20, 2013
P2, N=13, Completed, Sponsor: Onconova Therapeutics, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Trial completion: Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome (clinicaltrials.gov) - Dec 25, 2012
P4, N=42, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Recruiting --> Completed
- || Enrollment change: Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies (clinicaltrials.gov) - Nov 25, 2012
P=N/A, N=3000, Active, not recruiting, Sponsor: Sequenom, Inc.
Recruiting --> Completed N=1600 --> 3000
- Enrollment change: Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21 (clinicaltrials.gov) - Jun 18, 2012
P=N/A, N=2000, Recruiting, Sponsor: OVO R & D
N=1600 --> 3000 N=5000 --> 2000
- | Trial termination, Biopsy: Preimplantation Genetic Diagnosis (PGD) by Array Comparative Genome Hybridization (CGH) and Blastocyst Biopsy (clinicaltrials.gov) - May 24, 2012
P3, N=120, Terminated, Sponsor: Reprogenetics
N=5000 --> 2000 Recruiting --> Terminated; Not enough patients enrolling
- |||| Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Enrollment open: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - May 13, 2012
P2, N=60, Recruiting, Sponsor: Onconova Therapeutics, Inc.
Recruiting --> Terminated; Not enough patients enrolling Not yet recruiting --> Recruiting
- ||||| Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
New P2 trial: ONTARGET: Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 23, 2012
P2, N=60, Recruiting, Sponsor: Onconova Therapeutics, Inc.
- Enrollment open: Detecting Early Onset Pre-eclampsia and Use of Placental Growth Factor (PlGF) for Marker of Trisomy 21 (clinicaltrials.gov) - Apr 22, 2012
P=N/A, N=2000, Recruiting, Sponsor: OVO R & D
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Enrollment open: Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies (clinicaltrials.gov) - Mar 21, 2012
P=N/A, N=2200, Recruiting, Sponsor: Sequenom, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment change: INTREPID: Correlations Phenotype / Genotype in Down Syndrome (clinicaltrials.gov) - Mar 20, 2012
P=N/A, N=524, Completed, Sponsor: Institut Jerome Lejeune
Not yet recruiting --> Recruiting N=800 --> 524
- Trial completion: INTREPID: Correlations Phenotype / Genotype in Down Syndrome (clinicaltrials.gov) - Mar 20, 2012
P=N/A, N=524, Completed, Sponsor: Institut Jerome Lejeune
N=800 --> 524 Recruiting --> Completed
- Trial termination: Infant Weight Gain With Trisomy 21 and CAVC (clinicaltrials.gov) - Mar 13, 2012
P=N/A, N=46, Terminated, Sponsor: Children's Healthcare of Atlanta
Recruiting --> Completed Active, not recruiting --> Terminated; sufficient data collected for significant conclusion
- Enrollment change: Infant Weight Gain With Trisomy 21 and CAVC (clinicaltrials.gov) - Mar 13, 2012
P=N/A, N=46, Terminated, Sponsor: Children's Healthcare of Atlanta
Active, not recruiting --> Terminated; sufficient data collected for significant conclusion N=100 --> 46
- Tracleer (bosentan) / J&J, Roche
Trial completion: Pulmonary Hypertension in Trisomy 21 Patients (clinicaltrials.gov) - Mar 13, 2012
P=N/A, N=1, Completed, Sponsor: Children's Healthcare of Atlanta
N=100 --> 46 Active, not recruiting --> Completed